VVOS News and Press, Vivos Therapeutics Inc. From 12/14/21

mmRNA is the first and only appliance of its kind covered by Medicare Part of the Vivos System treatment, the mmRNA appliance represents a highly effective, non-surgical, non-invasive, and non-pharmaceutical alternative for patients suffering from OSA and snoring H...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, has registered with Health Canada...

Vivos Therapeutics (NASDAQ:VVOS) announces its official registration with Health Canada, which aims to provide patients with a comprehensive, end-to-end solution for obstructive sleep apnea (OSA) patients, which incorporates clinical screening, medical diagnosis and therapy using Vivos p...

HIGHLANDS RANCH, Colo., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for pa...

Obstructive sleep apnea (“OSA”) is a chronic sleep disorder that causes an individual’s breathing to stop and start while asleep. This disorder, which affects roughly one billion individuals globally, doubles the risk of the sudden death of these individuals, especia...

Obstructive sleep apnea ("OSA") is a common sleep-related breathing disorder that causes individuals to repeatedly start and stop breathing while they sleep. There exist different types of sleep apnea, with the most common one being obstructive sleep apnea. Common symptoms of this particul...

Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, has released is third-q...

Vivos Therapeutics, Inc. (VVOS) Q3 2021 Results Conference Call November 15, 2021 5:00 PM ET Company Participants Edward Loew - IR Kirk Huntsman - CEO Brad Amman - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Scott Henry - ROTH Capital Presentation Operator Good da...

Vivos Therapeutics (NASDAQ:VVOS): Q3 GAAP EPS of -$0.26 misses by $0.08. Revenue of $4.55M (+38.3% Y/Y) beats by $0.05M. Press Release For further details see: Vivos Therapeutics EPS misses by $0.08, beats on revenue

Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and Positive Study Results Management to Host Co...